Budesonide 160mcg, glycopyrrolate 9mcg, formoterol fumarate 4.8mcg ... and formoterol fumarate [BFF MDI 320 mcg/9.6 mcg], or open-label active comparator, all administered twice daily.
HealthDay on MSN13d
Study Compares Single-Inhaler Triple Therapies for Treatment of COPD
For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback